This course has expired. View available courses.
Respirology
Optimizing Anti-Inflammatory Reliever Therapy: A Fundamental Change in Approach to Treating Asthma
The key goals of asthma management are to avoid exacerbations and control symptoms. For many patients, symptom control means short-acting β2-agonist (SABA). However, SABA does not address the underlying inflammation of asthma.
The Global Asthma Initiative (GINA) now recommends that all adults and adolescents with asthma receive as needed low-dose inhaled corticosteroids (ICS)/formoterol as reliever, which will also act on inflammation with every inhalation, reducing risk of asthma exacerbations.
This program will review recent evidence supporting ICS/formoterol as both maintenance and reliever to better manage asthma and to avoid the risk of exacerbations and worsening asthma caused by overuse of SABA.
At the end of the program we will briefly touch on what is known about COVID-19 and asthma.
This program is developed in collaboration with Family Physician Airways Group of Canada, and has received an educational grant or in-kind support from AstraZeneca.
DURATION
1.5 hrs
PROFESSION
Physician, Medical Resident, Specialist
# OF CREDITS
1.5
ACCREDITATION
Mainpro+
EXPIRY DATE
2021-11-11
The key goals of asthma management are to avoid exacerbations and control symptoms. For many patients, symptom control means short-acting β2-agonist (SABA). However, SABA does not address the underlying inflammation of asthma.
The Global Asthma Initiative (GINA) now recommends that all adults and adolescents with asthma receive as needed low-dose inhaled corticosteroids (ICS)/formoterol as reliever, which will also act on inflammation with every inhalation, reducing risk of asthma exacerbations.
This program will review recent evidence supporting ICS/formoterol as both maintenance and reliever to better manage asthma and to avoid the risk of exacerbations and worsening asthma caused by overuse of SABA.
At the end of the program we will briefly touch on what is known about COVID-19 and asthma.
This program is developed in collaboration with Family Physician Airways Group of Canada, and has received an educational grant or in-kind support from AstraZeneca.
Faculty
Alan Kaplan, MD, CCFP(EM), FCFP
Mark FitzGerald, MB, MCh, BAO, MD, FRCPI, FRCPC, FACCP, FACP
Jacques Bouchard, MD, CCFP
Rakesh Patel, MB, BS, MRCGP (UK), CCFP
Learning objectives
Upon completion of this continuing education program participants will be better able to:
- Discuss why over-reliance on short-acting beta-agonists (SABA) increases risk of exacerbations and worsening asthma;
- Describe the latest asthma treatment recommendations from the Global, Initiative for Asthma (GINA) and the Canadian Thoracic Society (CTS);
- Identify strategies to transition patients from SABA as a reliever to anti-inflammatory reliever.
Accreditation
# of credits: 1.5
Duration: 1.5 hrs
FAQs & HELP
MDBriefCase Group specializes in accredited, online continuing professional development (CPD) programs, custom tailored for specific international markets and available on a convenient online platform.
All content is developed by leading specialists and peer-reviewed by experts at respected institutions, which keeps more than 280,000 global healthcare professionals at the forefront of the latest evidence and protocols worldwide.
The vast majority of our programs are accredited by one or more respected institutions. We do provide unaccredited content to ensure that healthcare professionals have access to relevant practical resources in addition to accredited learning.
Specific accrediting information (including the accrediting body, along with the type and number of credits) can be found on the “Main” page and/or “Accreditation” page of each program. In order to qualify for accreditation and obtain your certificate, you must successfully complete the requirements listed on the “Accreditation” or “CME Information” pages available in each program.
MDBriefCase Group works with various institutions to provide peer-reviewed, up-to-date accredited content. Our programs and resources are provided via collaboration between medical writers, faculty members, associations, universities and other relevant organizations. The content you were recommended is likely valued by your society or association and is conveniently provided to you free of charge on an MDBriefCase Group platform.
Specific accrediting information (including the accrediting body, along with the type and number of credits) can be found on the “Main” page and/or “Accreditation” page of each program. In order to qualify for accreditation and obtain your certificate, you must successfully complete the requirements listed on the “Accreditation” or “CME Information” pages available in each program.
If you are interested in learning more about supporting one of our programs, please contact us.
If you are interested in working with MDBriefCase Group as a writer or committee member, please contact us.
To access the MDBriefCase Group privacy policy, please click here.
No, registration with MDBriefCase is free!
To access your profile, visit My Profile. If you would like to update the information here don’t forget to hit the ‘save’ button when you are finished. Your profile is where you can control what email communications you receive.
If you have forgotten your password, you can reset your password. To access this page from the Login page, click Forgot password. Enter the email address you registered with and you will receive an email with a link to reset your password.
Please note: if you submitted multiple password resets, only the link on the most recent email is valid.
You can unsubscribe from MDBriefCase Group emails by clicking the unsubscribe button located at the bottom of each of our emails.
